Loading clinical trials...
Loading clinical trials...
The objective of this study is to evaluate the efficacy and safety of Chondron (Autologus Chondrocyte) in patients with cartilage defects in their ankle for 18 months
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Sewon Cellontech Co., Ltd.
NCT02519881 · Defect of Articular Cartilage
NCT01473199 · Cartilage Injury, Defect of Articular Cartilage, and more
NCT01626677 · Degenerative Osteoarthritis, Defect of Articular Cartilage
NCT01347892 · Defect of Articular Cartilage, Osteochondral Lesion of Talus, and more
NCT00881023 · Defect of Articular Cartilage, Osteochondritis Dissecans
Myongji Hospital
Goyang-si, Gyeonggi-do
Eulji General Hospital
Seoul, Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions